Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13258
UPID:
PD2R_HUMAN
Alternative names:
Prostanoid DP receptor
Alternative UPACC:
Q13258; G3V5L3; Q13250; Q13251; Q1ZZ52
Background:
The Prostaglandin D2 receptor, also known as the Prostanoid DP receptor, plays a pivotal role in mediating the effects of prostaglandin D2 (PGD2). This receptor's activation primarily triggers G(s) proteins, enhancing adenylate cyclase activity and raising intracellular cAMP levels. Additionally, it facilitates calcium mobilization, contributing to various physiological responses.
Therapeutic significance:
Given its involvement in asthma-related traits, including symptoms like coughing, wheezing, and dyspnea, the Prostaglandin D2 receptor is a key target in asthma research. Understanding its function could lead to novel therapeutic strategies for managing asthma and related conditions.